Sarepta Therapeutics Inc (SRPT) Stock AnalysisSRPTStock AnalysisSarepta Therapeutics Inc

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sarepta Therapeutics Inc (SRPT) is a good buy right now due to its current price of $20.86, which is significantly below the analyst price target of $35 from Oppenheimer, indicating a potential upside of 67.5%. Additionally, the stock has shown a strong 5-day change of +11.02% and a 20-day change of +40.38%, suggesting positive momentum. However, the main risk is highlighted by the negative sentiment from hedge funds, which have increased selling by 12693.27% over the last quarter.

18 analysts cover SRPT: 17 rate it Buy, 1 Hold and 0 Sell. The average price target is 20.80.